Related Experiment Video
Updated: Jul 4, 2025
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
The novel selective TLR7 agonist GY101 suppresses colon cancer growth by stimulating immune cells
Su-Mei Ren1, Jun-Biao Chang2, Rui-Qi Liu2
1Research Center of Basic Medicine, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450001, Henan, China.
Abstract:
Toll-like receptor (TLR) 7, a transmembrane signal transduction receptor expressed on the surface of endosomes, has become an attractive target for antiviral and cancer immunotherapies. TLR7 can induce signal transduction by recognizing single-stranded RNA or its analogs, leading to the release of cytokines such as IL-6, IL-12, TNF-α and type-I IFN. Activation of TLR7 helps to enhance immunogenicity and immune memory by stimulating immune cells. Herein, we identified a novel selective TLR7 agonist, GY101, and determined its ability to activate TLR7. In summary, in vitro, compound GY101 significantly induced the secretion of IL-6, IL-12, TNF-α and IFN-γ in mouse splenic lymphocytes; in vivo, peritumoral injection of GY101 significantly suppressed colon cancer CT26, as well as poorly immunogenic B16-F10 and 4T1 cancer cell-derived tumor growth by activating the infiltration of lymphocytes and polarization of M2-like macrophages into M1-like macrophages. These results demonstrate that GY101, as a potent TLR7 agonist, holds great potential for cancer immunotherapy.
Insights
A novel Toll-like receptor 7 (TLR7) agonist, GY101, effectively activates immune cells and suppresses tumor growth in preclinical models. This finding highlights GY101
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Toll-like receptor 7 (TLR7) is a key target for antiviral and cancer immunotherapies.
- TLR7 activation by single-stranded RNA analogs triggers cytokine release (IL-6, IL-12, TNF-α, type-I IFN) and enhances immune memory.
Purpose of the Study:
- To identify and characterize a novel selective TLR7 agonist, GY101.
- To evaluate the potential of GY101 as a cancer immunotherapy agent.
Main Methods:
- In vitro assessment of GY101's ability to induce cytokine secretion in mouse splenic lymphocytes.
- In vivo evaluation of GY101's anti-tumor efficacy against CT26, B16-F10, and 4T1 cancer cells via peritumoral injection.
- Analysis of immune cell infiltration and macrophage polarization (M2 to M1) in tumor microenvironments.
Main Results:
- GY101 significantly induced secretion of IL-6, IL-12, TNF-α, and IFN-γ in vitro.
- Peritumoral GY101 injection suppressed tumor growth in multiple cancer models.
- GY101 promoted lymphocyte infiltration and M2 to M1 macrophage polarization in tumors.
Conclusions:
- GY101 is a potent TLR7 agonist with significant anti-tumor activity.
- GY101 demonstrates potential as a novel therapeutic agent for cancer immunotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...